BETA TALASEMİ HASTALARINDA TOTAL ANTİOKSİDAN KAPASİTESİ BİLİRUBİN VE ÜRİK ASİT SEVİYESİ İLE İLİŞKİLİ DEĞİLDİR

Yıl 2020, Cilt: 83 Sayı: 4, 373 - 377, 19.10.2020

Zeynep Karakaş Yasin Yılmaz Dolay Damla Çelik Agageldi Annayev Serap Erdem Kuruca

Öz

Amaç: Beta talasemi hastalarında inefektif eritropoez ve çoklu transfüzyonlardan kaynaklanan demir birikimi, hastaları oksidatif strese maruz bırakmaktadır. Bu çalışmada, beta talasemi hastalarında total antioksidan ve oksidan kapasiteleri ile bunların endojen antioksidanlar (bilirubin, ürik asid) arasındaki ilişkinin değerlendirilmesi amaçlanmıştır. Gereç ve Yöntemler: Çalışmaya transfüzyon bağımlı 30, transfüzyon bağımlı olmayan 15 olmak üzere kırk beş beta talasemi hastası ve 20 sağlıklı birey katılmıştır. Analiz için total antioksidan ve total oksidan durum kitleri kullanılmıştır. Bulgular: Hastaların total antioksidan kapasitesi (TAK) sağlıklı bireylere göre anlamlı olarak yüksek saptanmıştır (2,75 vs. 2,10 mmol/L; p=0,01). Total bilirubin seviyesi transfüzyon bağımlı olmayan hastalarda, transfüzyon bağımlı hastalara oranla anlamlı olarak yüksek bulunmuştur (5,7±3,3 vs.1,9±1,4; p<0,001). Total antioksidan kapasite ile endojen antioksidan seviyeleri arasında anlamlı ilişki saptanmamıştır (p=0,20) Sonuç: Beta talasemi hastalarının total antioksidan kapasitesi, hastaların endojen antioksidan durumları ile direkt ilişkili olmayabilir.

Anahtar Kelimeler

Beta talasemi, antioksidan kapasitesi, oksidan kapasitesi, endojen antioksidan

THE TOTAL ANTIOXIDANT CAPACITY MAY NOT BE RELATED TO BILIRUBIN AND URIC ACID LEVEL IN PATIENTS WITH BETA THALASSEMIA

Öz

Objective: Iron burden resulting from ineffective erythropoiesis and multiple transfusions can cause oxidative stress in patients with ß-thalassemia. Here we aimed to examine the total antioxidant and oxidant capacity (TAC and TOC) along with its relation to endogenous antioxidants (bilirubin and uric acid) in patients with ß-thalassemia. Materials and Methods: Forty-five patients with transfusion-dependent (TDT) (n=30) and non-transfusion-dependent (NTDT) (n=15) ß-thalassemia and 20 healthy subjects were enrolled in the study. Analyses were done using Total Antioxidant Status (TAS) and Total Oxidant Status (TOS) kits. Results: The TAC level of the patients was significantly increased compared to healthy subjects (2.75 vs. 2.10 mmol/L; p=0.01). The total bilirubin level was significantly elevated in NTDT patients compared to TDT patients (5.7±3.3 vs.1.9±1.4; p<0.001). No significant relationship between endogenous antioxidants and total antioxidant capacity of patients was detected (p=0.20) Conclusion: The total antioxidant capacity of patients with ß-thalassemia might not be directly related to endogenous anti- oxidative status.

Anahtar Kelimeler

Beta-thalassemia, antioxidant capacity, oxidant capacity, endogenous antioxidant

Kaynakça

• 1. Viprakasit V, Origa R. Genetic basis, pathophysiology and diagnosis. In: Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V, eds. Guidelines for the management of transfusion dependent thalassaemia (TDT). Nicosia: Thalassaemia International Federation (TIF) Publication, No. 20, third ed; 2014. p. 14-26.
• 2. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005;353:1135-46.
• 3. Bartosz G. Non-enzymatic antioxidant capacity assays: Limitations of use in biomedicine. Free Radic Res 2010;44(7):711-20.
• 4. Apak R, Gorinstein S, Böhm V, Schaich KM, Ozyurek M, Guclu K. Methods of measurement and evaluation of natural antioxidant capacity/activity (IUPAC Technical Report). Pure Appl. Chem 2013;85:957-98.
• 5. Niki E. Assessment of Antioxidant Capacity in vitro and in vivo. Free RadicBiol Med 2010;49:503-15.
• 6. Dilis V, Trichopoulou A. Assessment of antioxidants in foods and biologicalsamples: a short critique. Int J Food Sci Nutr 2010;61(5):441-8.
• 7. Rachmilewitz EA, Giardin PJ. How I treat thalassemia. Blood 2011;118:3479-88.
• 8. Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet 2018;391:155-67.
• 9. Asif M, Manzoor Z, Farooq MS, Munawar SH, Aziz A, Khan IA. Status of oxidant, antioxidantand serum enzymes in thalassaemic children receiving multiple blood transfusions. J Pak Med Assoc 2015;65(8):838-43.
• 10. Ferro E, Visalli G, La Rosa MA, Civa R, Papa GR, D’Ascola DG, et al. The role of anaemia in oxidative and genotoxic damage in transfused ß-thalassaemic patients. Hematology 2017;22:183-91.
• 11. Bazvand F, Shams S, BorjiEsfahani M, Koochakzadeh L, Monajemzadeh M, Ashtiani MT, et al. Total Antioxidant Status in Patients with Major ß-Thalassemia. Iran J Pediatr 2011;21(2):159-65.
• 12. Cakmak A, Soker M, Koc A, Erel O. Paraoxonase and arylesteraseactivity with oxidative status in children with thalassemia major. J Pediatr Hematol Oncol 2009;31:583-7.
• 13. Hamed EA, El Melegy NT. Renal functions in pediatric patients withbeta-thalassemia major: relation to chelation therapy: originalprospective study. Ital J Pediatr 2010;36:39- 42.
• 14. Manafikhi H, Drummen G, Palmery M, Peluso I. Total Antioxidant Capacity in beta-thalassemia: A systematic review and meta-analysis of case-control studies. Crit Rev Oncol Hematol 2017;110:35-42.